PL2274005T3 - Leczenie chorób nowotworowych z użyciem konwertazy angiotensyny 2 (ace2) - Google Patents

Leczenie chorób nowotworowych z użyciem konwertazy angiotensyny 2 (ace2)

Info

Publication number
PL2274005T3
PL2274005T3 PL09730771T PL09730771T PL2274005T3 PL 2274005 T3 PL2274005 T3 PL 2274005T3 PL 09730771 T PL09730771 T PL 09730771T PL 09730771 T PL09730771 T PL 09730771T PL 2274005 T3 PL2274005 T3 PL 2274005T3
Authority
PL
Poland
Prior art keywords
ace2
tumors
treatment
converting enzyme
angiotensin converting
Prior art date
Application number
PL09730771T
Other languages
English (en)
Inventor
Evelyne Janzek-Hawlat
Hans Loibner
Manfred Schuster
Bernhard Peball
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of PL2274005T3 publication Critical patent/PL2274005T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09730771T 2008-04-09 2009-04-07 Leczenie chorób nowotworowych z użyciem konwertazy angiotensyny 2 (ace2) PL2274005T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen
PCT/AT2009/000136 WO2009124330A2 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen
EP09730771.4A EP2274005B1 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen durch angiotensin konvertierendes enzym 2 (ace2)

Publications (1)

Publication Number Publication Date
PL2274005T3 true PL2274005T3 (pl) 2013-12-31

Family

ID=41130316

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09730771T PL2274005T3 (pl) 2008-04-09 2009-04-07 Leczenie chorób nowotworowych z użyciem konwertazy angiotensyny 2 (ace2)

Country Status (12)

Country Link
US (1) US8946162B2 (pl)
EP (2) EP2274005B1 (pl)
JP (1) JP5650639B2 (pl)
AT (1) AT506632A1 (pl)
AU (1) AU2009235931B2 (pl)
CA (1) CA2720616C (pl)
DK (1) DK2274005T3 (pl)
ES (1) ES2425308T3 (pl)
NZ (1) NZ588435A (pl)
PL (1) PL2274005T3 (pl)
PT (1) PT2274005E (pl)
WO (1) WO2009124330A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP3647790A1 (en) 2012-06-06 2020-05-06 Attoquant Diagnostics GmbH Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
CA2897251C (en) * 2013-01-14 2022-07-12 Apeiron Biologics Ag Modified ace2 polypeptides
WO2015086774A1 (en) * 2013-12-11 2015-06-18 Attoquant Diagnostics Gmbh Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
WO2018204385A1 (en) * 2017-05-02 2018-11-08 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
EP3717077A1 (en) 2017-11-29 2020-10-07 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230181759A1 (en) * 2020-04-01 2023-06-15 Washington University Compositions for treatment of viral respiratory infections and methods of use thereof
CN112626099A (zh) * 2020-09-29 2021-04-09 清华大学 使用原核细胞发酵表达血管紧张素转化酶2的方法
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2023102156A1 (en) 2021-12-03 2023-06-08 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
CA2475953A1 (en) * 2002-02-27 2003-09-04 E. Ann Tallant Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
ES2424971T3 (es) * 2002-06-19 2013-10-10 Apeiron Biologics Ag Activación de ECA2 para el tratamiento de enfermedades cardíacas, pulmonares y renales e hipertensión
EP1374907A3 (en) 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid

Also Published As

Publication number Publication date
US20110033524A1 (en) 2011-02-10
AT506632A1 (de) 2009-10-15
AU2009235931B2 (en) 2015-07-23
EP2274005B1 (de) 2013-05-29
EP2274005A2 (de) 2011-01-19
AU2009235931A1 (en) 2009-10-15
NZ588435A (en) 2012-10-26
CA2720616C (en) 2016-08-09
ES2425308T3 (es) 2013-10-14
WO2009124330A3 (de) 2009-12-10
PT2274005E (pt) 2013-08-27
US8946162B2 (en) 2015-02-03
JP2011516501A (ja) 2011-05-26
DK2274005T3 (da) 2013-08-19
CA2720616A1 (en) 2009-10-15
EP2644203A1 (de) 2013-10-02
JP5650639B2 (ja) 2015-01-07
WO2009124330A2 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
PL2274005T3 (pl) Leczenie chorób nowotworowych z użyciem konwertazy angiotensyny 2 (ace2)
EP2322076A4 (en) ENDOSCOPE OF TREATMENT
GB0812712D0 (en) Improved endoscope
EP2273880A4 (en) NOVEL COMPOSITIONS FOR THE TREATMENT OF MIGRAINE
ZA201008392B (en) Treatment of pluripotent cells
IL208354A0 (en) Methods of treatment
EP2459565A4 (en) METHOD AND COMPOSITIONS FOR STUDYING, PRESENTING AND TREATING PAIN
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
GB0808711D0 (en) Tissue assessment
EP2249789A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY
EP2321760A4 (en) PRESENTATION OF SECURITY IDENTITY BY REQUIREMENTS
EP2368499A4 (en) TREATMENT INSTRUMENT
ZA201000225B (en) Treatment of depression
WO2009151620A9 (en) Pain treatment using erk2 inhibitors
GB0818328D0 (en) Novel enzyme
GB0804721D0 (en) Enzyme
GB0803628D0 (en) Enzyme
GB0804722D0 (en) Enzyme
IL207848A0 (en) Artificial enzymes
GB0811210D0 (en) Improvements related to the authentication of messages
GB0805831D0 (en) Authentication of broadcasts
EP2349299A4 (en) COMPOSITION FOR THE TREATMENT OF HYPERTENSION
EP2328577A4 (en) TREATMENT OF LOSS OF HEARING
AU2008904170A0 (en) Treatment of coal
AU2008905626A0 (en) Water treatment